Reported 26 days ago
Moderna has pushed back its break-even goal by two years and projected lower sales for 2025, leading to a drop in its stock price. Analyst Michael Yee downgraded the company's stock, citing disappointing guidance for COVID and RSV segments, concerns over cash burn, and a potentially problematic outlook for future revenue and product development in a highly competitive biotech sector.
Source: YAHOO